Nonserious postmarket adverse event report waivers may be sought by firms, FDA says.
This article was originally published in The Tan Sheet
Executive Summary
NONSERIOUS POSTMARKETING ADVERSE EVENT REPORT WAIVERS may be sought by manufacturers for drugs, such as Rx-to-OTC switches, and some biologics, FDA indicates in a clarification of agency adverse event reporting requirements. "FDA is willing to entertain waiver requests for periodic submission of individual case reports for adverse experiences that are determined to be nonserious and labeled," an Aug. 27 agency guidance states.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning